Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect and the side effect profile of
irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with
metastatic colorectal cancer without KRAS mutations.